{"title":"超越监管:与Robert Califf博士就医疗保健面临的挑战和创新社区解决方案进行对话:美国如何利用技术创新改变其医疗保健系统以改善人口健康结果?","authors":"Robert M Califf, Danea M Horn, Kathryn A Phillips","doi":"10.1093/haschl/qxaf075","DOIUrl":null,"url":null,"abstract":"<p><p>Dr. Robert M. Califf recently ended his second tenure as the Commissioner of the Food and Drug Administration (FDA). Our conversation occurred on his 1-month anniversary of becoming a private citizen again. In our conversation, Dr. Califf shares his perspective on pressing healthcare challenges following his second tenure as FDA Commissioner. Dr. Califf discusses the balancing act between accelerated drug approvals and evidence generation, emphasizing the need for robust postmarket studies and the health system's role in evidence generation. He also advocates for a fundamental shift toward prevention-focused, community-based healthcare supported by technology to address the paradox of spending and health outcomes in the United States. As healthcare leadership in the new administration shifts health priorities, Dr. Califf highlights critical vulnerabilities in pharmaceutical supply chains and the urgent need to combat health misinformation in the digital age.</p>","PeriodicalId":94025,"journal":{"name":"Health affairs scholar","volume":"3 5","pages":"qxaf075"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063077/pdf/","citationCount":"0","resultStr":"{\"title\":\"Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions: How can the United States harness technological innovation to transform its healthcare system to improve population health outcomes?\",\"authors\":\"Robert M Califf, Danea M Horn, Kathryn A Phillips\",\"doi\":\"10.1093/haschl/qxaf075\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dr. Robert M. Califf recently ended his second tenure as the Commissioner of the Food and Drug Administration (FDA). Our conversation occurred on his 1-month anniversary of becoming a private citizen again. In our conversation, Dr. Califf shares his perspective on pressing healthcare challenges following his second tenure as FDA Commissioner. Dr. Califf discusses the balancing act between accelerated drug approvals and evidence generation, emphasizing the need for robust postmarket studies and the health system's role in evidence generation. He also advocates for a fundamental shift toward prevention-focused, community-based healthcare supported by technology to address the paradox of spending and health outcomes in the United States. As healthcare leadership in the new administration shifts health priorities, Dr. Califf highlights critical vulnerabilities in pharmaceutical supply chains and the urgent need to combat health misinformation in the digital age.</p>\",\"PeriodicalId\":94025,\"journal\":{\"name\":\"Health affairs scholar\",\"volume\":\"3 5\",\"pages\":\"qxaf075\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063077/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health affairs scholar\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/haschl/qxaf075\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health affairs scholar","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/haschl/qxaf075","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Robert M. Califf博士最近结束了他作为食品和药物管理局(FDA)局长的第二个任期。我们的谈话发生在他再次成为普通公民的一个月纪念日。在我们的谈话中,Califf博士分享了他在担任FDA专员的第二个任期后对紧迫的医疗保健挑战的看法。Califf博士讨论了加速药物批准和证据生成之间的平衡行为,强调需要进行强有力的上市后研究和卫生系统在证据生成中的作用。他还主张从根本上转向以预防为重点,以技术为支持的社区医疗保健,以解决美国支出和健康结果之间的悖论。随着新政府的医疗保健领导层转移卫生重点,卡利夫博士强调了药品供应链中的关键漏洞,以及在数字时代打击卫生错误信息的迫切需要。
Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions: How can the United States harness technological innovation to transform its healthcare system to improve population health outcomes?
Dr. Robert M. Califf recently ended his second tenure as the Commissioner of the Food and Drug Administration (FDA). Our conversation occurred on his 1-month anniversary of becoming a private citizen again. In our conversation, Dr. Califf shares his perspective on pressing healthcare challenges following his second tenure as FDA Commissioner. Dr. Califf discusses the balancing act between accelerated drug approvals and evidence generation, emphasizing the need for robust postmarket studies and the health system's role in evidence generation. He also advocates for a fundamental shift toward prevention-focused, community-based healthcare supported by technology to address the paradox of spending and health outcomes in the United States. As healthcare leadership in the new administration shifts health priorities, Dr. Califf highlights critical vulnerabilities in pharmaceutical supply chains and the urgent need to combat health misinformation in the digital age.